Pfizer Vice President Blows The Whistle & Tells The Truth About The Pharmaceutical Industry

[shambles]

Not anything we didn't know already.

collective-evolution.com/20...

“It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of the New England Journal of Medicine.” – Dr. Marcia Angell, a physician and longtime editor-in-chief of the New England Medical Journal (NEMJ) (source)

[Clutter]

Thanks for posting, Shambles. I'd like to see drug licenses withheld until all research into new drugs is made available for review. Long term follow up studies should also be done.

[shambles in reply to Clutter]

Yes I agree Clutter. In today's technology you would think that there should be a central world file for each an every type of illness with cross reference to all research.

At least things are moving in the right direction with AllTrails pushing for all research to be made available.

I've just started reading Dr Ben Goldacre's Bad Pharma today.

[Clutter in reply to shambles]

Shambles, I haven't read the book but I support Ben Goldacre's efforts with AllTrials and hope it will be adopted sooner rather than later.

[Rosy_Holly]

All trials are very busy at the moment battling away in court to see that all information regarding drug research is made available. They are not having an easy time. The company apposing this keeps changing the goal posts. Lawyers appointed by AllTrials are having to work 24/7 to keep up.

[shambles in reply to Rosy_Holly]

Rosy_Holly I have just started reading about research and how they are used or not as the case my be.

I wholly admire AllTrails and did not know they existed until recently. It's such a shame that more people are not aware or a locked in on the impact of what must be soul distroying for individuals who are involved in the field of research.

It's a big subject.